Comparing two methods for stopping high flow nasal cannula treatment in infants with acute bronchiolitis
Official title: High Flow Nasal Cannula Weaning in Acute Bronchiolitis - an Open-label Randomized Controlled Trials
Run by Kuopio University Hospital · NCT06321133 · Data updated 2026-11-12
This study is testing whether stopping high flow nasal cannula treatment right away or gradually is better for helping infants with acute bronchiolitis leave the hospital sooner and safely.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 0 Months to 12 Months |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Kuopio University Hospital Academic / other |
| Locations | 4 sites (Joensuu and 3 other locations) |
| Status | Recruiting |
| Started | February 13, 2024 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2028 |
| Registry record updated | September 3, 2025 |
| Trial ID | NCT06321133 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are infants diagnosed with acute bronchiolitis who have been on high flow nasal cannula treatment for at least 12 hours and have stable oxygen saturation.
✕Probably not a fit
Patients with major congenital anomalies of the lungs, heart, or diaphragm, or those with bacterial pneumonia may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical study aims to compare two strategies for discontinuing high flow nasal cannula treatment in infants diagnosed with acute bronchiolitis. One group will have their treatment stopped immediately, while the other will undergo a gradual weaning process. The study will assess whether immediate cessation can shorten hospitalization time and determine the safety of this approach. Given the lack of effective pharmacological treatments for acute bronchiolitis, this research seeks to provide evidence-based guidance on the management of this common condition in infants.
Why it matters
Potential benefit: If successful, this study could lead to shorter hospital stays for infants suffering from acute bronchiolitis.
How similar studies have gone: While other observational studies have suggested that immediate cessation may be beneficial, this is the first randomized trial specifically focused on bronchiolitis patients.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinically diagnosed acute bronchiolitis * High flow nasal cannula treatment has lasted for at least 12 hours * Measured saturation 95 or more with room air * High flow rate is maximum 2l/kg/min * The treating doctors considers the infant suitable to be without high flow Exclusion Criteria: * Major congenital anomaly of lungs, hearts or diaphragm * Bacterial pneumonia * Parents do not give consent
Where it's running
-
Siun Sote
Joensuu, Finland Recruiting -
Central Finland Hospital District
Jyväskylä, Finland Recruiting -
Kuopio University Hospital
Kuopio, Finland Recruiting -
Mikkeli Central Hospital
Mikkeli, Finland Recruiting
Study contacts
- Study coordinator: Ilari Kuitunen, MD, PhD
- Email: ilari.kuitunen@uef.fi
- Phone: +358447174910
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Montelukast for acute bronchiolitis in infants and young children
This study tests whether adding montelukast to standard care helps shorten hospital stays and relieve symptoms in indoor patients aged 4 weeks to 2 years with acute bronchiolitis.
-
Shortening antibiotic courses for common throat and chest infections in primary care with doctor–pharmacist teamwork and viral‑circulation updates
This project will test whether giving primary care doctors and pharmacists extra information about circulating viruses plus a shared protocol helps shorten antibiotic courses for patients with common respiratory infections.
-
Understanding viral infections in infants with bronchiolitis after Nirsevimab use
This study looks at how the use of Nirsevimab affects the types of viral infections in infants under one year old who have their first episode of bronchiolitis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.